{"id":2917,"date":"2016-11-17T21:52:02","date_gmt":"2016-11-17T21:52:02","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=18393"},"modified":"2016-11-17T21:52:02","modified_gmt":"2016-11-17T21:52:02","slug":"axim-biotechnologies-patent-delayed-release-cannabidiol-gum-extended-include-cannabinoids","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/11\/17\/axim-biotechnologies-patent-delayed-release-cannabidiol-gum-extended-include-cannabinoids\/","title":{"rendered":"AXIM\u00ae Biotechnologies Patent on Delayed Release Cannabidiol Gum Extended to Include All Cannabinoids"},"content":{"rendered":"
Medical Marijuana, Inc. investment company <\/span>AXIM\u00ae Biotechnologies<\/span><\/a> announced this week that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application Serial Number <\/span>9,433,601<\/span><\/a>, a patent owned by the company that claims the use of all cannabinoids (botanical and synthetic) in cannabinoid-infused controlled-release chewing gum products. <\/span><\/p>\n AXIM\u00ae Biotechnologies filed this patent application in April 2015. The Notice of Allowance was issued after the USPTO made the determination that the patent can be granted from the application. This most recent patent covers the inclusion of all cannabinoids, including Tetrahydrocannabinol (THC), in a chewing gum controlled-release delivery system, giving the company exclusive rights to incorporate cannabinoids into the company’s chewing gum products.<\/span><\/p>\n The company\u2019s new patent is an extension of AXIM\u00ae Biotechnologies’ original patent for chewing gum as a delivery method for cannabidiol (CBD). Prior to this new allowance, AXIM\u00ae\u2019s patent <\/span>9,023,322<\/span><\/a> only claimed gum products as a delivery mechanism for CBD. With the new extension, AXIM\u00ae can develop products containing the full-range of available cannabinoids including THC, the most commonly known cannabinoid. <\/span><\/p>\n \u201cThis new patent extension is a huge step forward for AXIM\u00ae as it now encompasses an additional 85+ cannabinoids, as well as the unlimited combinations of these therapeutic compounds,\u201d Medical Marijuana, Inc. CEO Dr. Stuart Titus said, \u201cThis is strategically important for AXIM\u00ae as the company searches for answers to specific disease indications – utilizing both botanical and\/or synthetic cannabinoid formulations. No other group may introduce a rival cannabinoid product with this delivery mechanism.\u201d<\/span><\/p>\n Using their patents, AXIM\u00ae Biotech has developed several unique cannabinoid-based chewing gum products exclusive to their company. <\/span><\/p>\n AXIM\u00ae\u2019s CBD-only <\/span>Canchew\u00ae <\/span><\/a>hemp oil products are legal to purchase and ship wherever CBD hemp oil products are available. CanChew\u00ae is a natural hemp-derived CBD chewing gum with a specialized oral mucosal absorbance delivery system. AXIM\u00ae Biotech holds the exclusive rights to market and distribute CanChew\u00ae CBD-infused chewing gum globally. <\/span><\/p>\n Worldwide, the <\/span>yearly chewing gum market<\/span><\/a> is valued at $25.8 billion, with $3.9 billion in sales coming from North America. Meanwhile, combined sales of cannabinoid-infused products are expected to reach <\/span>$2.7 billion a year<\/span><\/a>. By combining these two prevalent markets, AXIM\u00ae Biotechnologies hopes to tap into a vast and growing worldwide market for its cannabinoid-based chewing gum products. <\/span><\/p>\n